QTTB — Q32 Bio Income Statement
0.000.00%
Last trade - 00:00- $18.91m
- -$46.41m
Annual income statement for Q32 Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2.7 | 34 | 3.21 | 1.16 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 133 | 130 | 5.24 | 93.8 | 66.8 |
| Operating Profit | -130 | -95.9 | -2.03 | -92.7 | -66.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -129 | -95.8 | 1.2 | -87.1 | -46.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -129 | -95.8 | 0.483 | -87.1 | -46.1 |
| Equity in Affiliates | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -129 | -95.8 | -5 | -113 | -47.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -129 | -95.8 | -5 | -113 | -47.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -50.5 | -31.2 | -28.3 | -35 | -5.07 |